SCHEMBL12156331

SCHEMBL12156331

CCc1c(C(C)NS(=O)(=O)c2ccc(Cl)c(Cl)c2)ccnc1Oc1cccc(N2CCOCC2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.41
BRD4 O60885 2/20 0.39
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
MMP1 P03956 1/20 0.37
MMP2 P08253 1/20 0.37
MMP3 P08254 1/20 0.37
MMP13 P45452 1/20 0.37
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
GUSB P08236 1/20 0.36
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 1/20 0.35
HPGD P15428 1/20 0.35
CCR2 P41597 4/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12156390 0.95 S1PR1 (0.42) S1PR1SMN1; SMN2BRD4PTGS1PTGS2
SCHEMBL12156387 0.93 S1PR1 (0.43) S1PR1SMN1; SMN2BRD4PTGS1PTGS2
SCHEMBL12156416 0.93 S1PR1 (0.41) S1PR1SMN1; SMN2BRD4PTGS1PTGS2
SCHEMBL12156381 0.92 S1PR1 (0.51) S1PR1SMN1; SMN2BRD4PTGS1PTGS2
SCHEMBL1705603 0.92 SMN1; SMN2 (0.40) SMN1; SMN2BRD4GUSBCCR2
SCHEMBL1706085 0.92 SMN1; SMN2 (0.40) SMN1; SMN2BRD4GUSBCCR2
SCHEMBL1705567 0.92 SMN1; SMN2 (0.40) SMN1; SMN2BRD4GUSBCCR2
SCHEMBL1706084 0.90 S1PR1 (0.42) S1PR1SMN1; SMN2BRD4PTGS1PTGS2
SCHEMBL12156366 0.90 S1PR1 (0.43) S1PR1SMN1; SMN2BRD4PTGS1PTGS2
SCHEMBL12156362 0.90 S1PR1 (0.42) S1PR1SMN1; SMN2BRD4PTGS1PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8048898-B2 Inhibitor of binding of S1P1 TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-11-01 US disclosed
US-8048898-B2 Inhibitor of binding of S1P1 TAISHO PHARMACEUTICAL CO., LTD (JP) 2011-11-01 US disclosed
US-20100234594-A1 INHIBITOR OF BINDING OF S1P1 TAISHO PHARMACEUTICAL CO., LTD. (JP) 2010-09-16 US disclosed
US-20100234594-A1 INHIBITOR OF BINDING OF S1P1 TAISHO PHARMACEUTICAL CO., LTD. (JP) 2010-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234594-A1 INHIBITOR OF BINDING OF S1P1 S1PR1, S1PR3, EDNRB S1PR1 1/4885SMN1; SMN2 1995/4885BRD4 3068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.